New 'Double-Action' drug tested to shrink lung tumors before surgery
NCT ID NCT07359040
Summary
This study is testing a new drug called Ivonescimab for people with non-small cell lung cancer who need surgery. It compares this new drug, which works by blocking two different cancer pathways at once, to standard immunotherapy drugs. The main goal is to see if the new drug is better at shrinking or eliminating the tumor before the operation and to understand exactly how it works in the body.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking University People's Hospital
Beijing, Beijing Municipality, 100044, China
Conditions
Explore the condition pages connected to this study.